Article Text

Download PDFPDF

2022-RA-822-ESGO Risk reducing surgery in ovarian cancer
  1. Vera Loizzi1,
  2. Francesca Arezzo2,
  3. Isabella Romagno3,
  4. Miriam Dellino4,
  5. Erica Silvestris2,
  6. Anila Kardhashi2,
  7. Gerardo Cazzato5,
  8. Leonardo Resta5,
  9. Francesco Legge6,
  10. Luca Damiani7,
  11. Iole Natalicchio8,
  12. Nicoletta Resta9,
  13. Ettore Cicinelli9 and
  14. Gennaro Cormio2
  1. 1DIM, University of Bary, ITALY, BARI, Italy
  2. 2IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy, bari, Italy
  3. 3univeristy of bari, bari, Italy
  4. 4Department of Obstetrics and Gynecology, San Paolo Hospital, Bari, Italy, Bari, Italy
  5. 5Section of Pathology, Department of emergency and organ transplantation, University of Bari, Italy, bari, Italy
  6. 6Miulli Hospital, Acquaviva, Bary, Italy, bari, Italy
  7. 7policlinico hospital Bari, Bari, Italy
  8. 8Section Of Clinic Pathologic, OORR, Foggia, Italy, bari, Italy
  9. 9Department of Biomedical Sciences and human Oncology (DIMO), University of Bari, Italy, bari, Italy


Introduction/Background The study evaluated the risk of ovarian cancer in women with BRCA 1–2 mutations. BRCA 1–2 are tumor-suppressor genes involved in DNA homologous recombination and ovarian cancer development

Methodology From 2016 to may 2022, all risk reducing surgery (RRSO) which included salpingo-oophorectomy was performed in all patients carrying BRCA1 and BRCA 2 mutation.

Results We collected 172 women. The median age of BRCA 1 mutated patients was 51 aged (range 30–73 years), whereas the median age of BRCA 2 mutated patients was 53 (range 36–70). One hundred and three patients had previous history of breast cancer. Among the 172, 145 (85%) underwent risk reducing salpingo-oohorectomy (RRSO) though a laparoscopic minimally invasive approach. 12 (7%) underwent laparoscopic RRSO and contextual hysterectomy, 3 (2%) underwent RRSO through a laparotomic approach and 10 (6%) laparotomic RRSO and hysterectomy. During 8 (5%) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complications occurred in 3 patients (2%). Four patients (2%) were found to have occult serous tubal intraepithelial carcinoma (STIC) and nine patients (5%) occult cancer.

Conclusion RRSO is a safe and feasible procedure in BRCA 1–2 mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.